Ronda Rippley

WORK HISTORY

EDUCATION

ABOUT RONDA RIPPLEY

Highly experienced biotech/pharma executive with a track record of setting strategic direction and building teams and organizations that that deliver pipeline and business value. Empowering and emotionally intelligent, I bring strong organizational leadership acumen, deep expertise in preclinical development sciences, clinical pharmacology, and model-informed drug discovery and development, and a proven ability to leverage translational capabilities to drive increased probability of technical success and confidence in clinical proof of concept. Highlights:Skillful builder of organizations with core capabilities that deliver clear scientific and business impact• As function and subdivision head at 4 different companies, I have either built anew or transformed an existing organization to deliver key portfolio impact• Emphasis on driving program and regulatory decisions through core functional expertise and advanced strategic contributions• Extensive experience in targeted hiring and development to enrich leadership, critical thinking, and strategic skills • Experience leading multi-function, multi-site, and multi-national organizations.Unique background, with diverse industry experience• Engineering education with strong problem solving and computational skills combined with over 15 years developing and applying leadership acumen in organizations large and small• Successful in a variety of business models, including conventional large pharma, large biotech, emerging mid-size biotech, and private small biotech• Able to deliver across functional sourcing models from internal resource-intensive approaches to “virtual” largely externalized organizationsBroad drug development expertise• Led preclinical development and clinical pharmacology contributions to 10 development candidate milestone decisions, 5 INDs, and 3 FIH starts, and 1 Ph 2 start in 4 years at Blueprint Medicines• Discovery (hit-to-lead forward) through regulatory registration and lifecycle management, co-author of one BLA, four sNDAs, and two sBLAs; Clin Pharm/QP lead for two major late-stage projects• Small and large molecule expertise across mast cell disorders, heme-oncology, thrombosis, diabetes, hypertension, osteoporosis, anemia, pain, immunoncology, infectious disease, lipodystrophy, and complement disorder• Scientific contributions to critical early stage decisions, large-scale Phase2/3 programs, successful regulatory approvals, and 8 marketed products